GlaxoSmithKline is pinning the future of its HIV business on an audacious bet: upending the decades-old triple-drug treatment strategy that has turned a fatal illness into a chronic condition.
WSJ.com: Health, Wall Street Journal: Business: Health
Sun, 08/28/2016 - 11:40am
GlaxoSmithKline is pinning the future of its HIV business on an audacious bet: upending the decades-old triple-drug treatment strategy that has turned a fatal illness into a chronic condition.